Pharma Sector: Long a Target for Antitrust Enforcers

    View Authors July 2016

    Many features of the pharmaceutical sector make it prone to antitrust scrutiny. Intellectual property rights, in particular patents, and the promise of monopoly rents while patents remain valid, play a crucial role in incentivising new product research and development.

    An article authored by antitrust partners Diarmuid Ryan and Martin Rees, published in Volume 21, Issue 3 (2016) of the European Pharmaceutical Review, examines how the European Commission and the various national competition authorities throughout the EU have applied the EU competition rules to break down barriers to trade between EU countries.